OraSure Technologies Appoints New Chief Science Officer
April 15 2016 - 6:00AM
OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that
Michael Reed, Ph.D. has been named as the Company’s Senior Vice
President of Research and Development and Chief Science Officer. He
will begin working at the Company on April 18, 2016.
Dr. Reed brings to OraSure Technologies more than 20 years of
experience in life sciences and diagnostics research and
development across an extensive array of disciplines including
globally regulated IVD development and commercialization of
molecular and cellular applications and systems. He joins OraSure
after having spent the last eight years as part of the management
team at Beckman Coulter, a global diagnostics and life sciences
company within the Danaher Corporation.
At Beckman Coulter, Dr. Reed served in a variety of leadership
positions including Director of Global Assay and Applications
Development for the Beckman Coulter Life Science business
encompassing flow cytometry, genomics and capillary electrophoresis
reagent development and Director of Scientific Affairs for
the Cellular Analysis Business Group, including flow cytometry and
hematology reagent research and development, and clinical affairs.
Under his leadership, the Company launched and commercialized over
300 products globally across multiple disciplines.
Prior to his work at Beckman Coulter, Dr. Reed served as
Director of Product Development with Osmetech Molecular Diagnostics
where he led the effort to develop two U.S. FDA 510K cleared IVD
systems for cystic fibrosis genotyping and a pharmacogenetics test
to guide warfarin dosing. He also worked at the predecessor company
– Clinical Micro Sensors.
“Mike will be a valuable addition to our senior management team
and we will benefit from his global leadership in research and
development and specifically his expertise in regulated assay
development, genomics and molecular diagnostics,” stated Douglas A.
Michels, President and CEO of OraSure Technologies.
Dr. Reed received a Ph.D. degree in Biochemistry from the
University of Adelaide (Australia) and a BSc. in Biochemistry from
The Australian National University (Canberra, Australia). He
conducted post-doctoral research at the Beckman Research Institute
at the City of Hope in Duarte, California.
About OraSure
TechnologiesOraSure Technologies is a leader in
the development, manufacture and distribution of point of care
diagnostic and collection devices and other technologies designed
to detect or diagnose critical medical conditions. Its
first-to-market, innovative products include rapid tests for the
detection of antibodies to HIV and HCV on the OraQuick® platform,
oral fluid sample collection, stabilization and preparation
products for molecular diagnostic applications, and oral fluid
laboratory tests for detecting various drugs of abuse. OraSure's
portfolio of products is sold globally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, research and academic
institutions, distributors, government agencies, physicians'
offices, commercial and industrial entities and consumers. The
Company's products enable healthcare providers to deliver critical
information to patients, empowering them to make decisions to
improve and protect their health.
For more information on OraSure Technologies, please visit
www.orasure.com.
Investor Contact:
Ronald H. Spair
Chief Financial Officer
(610) 882-1820
investorinfo@orasure.com
Media Contact:
Ron Ticho
SVP, Corporate Communications
(484) 353-1575
media@orasure.com
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Apr 2023 to Apr 2024